OncoMatch

OncoMatch/Clinical Trials/NCT06727773

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

Is NCT06727773 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Memantine for breast cancer.

Phase 2RecruitingUNC Lineberger Comprehensive Cancer CenterNCT06727773Data as of Sep 2026

Treatment: MemantineThis randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, brain-derived neurotrophic factor (BDNF), inflammatory markers, and frailty at multiple time points.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Memantine

Cancer type

Breast Carcinoma

Disease stage

Required: Stage I, II, III

Demographics

Female only

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

Exception: prior to the current regimen

Previous chemotherapy (prior to the current regimen)

Lab requirements

Kidney function

crcl > 5 ml/min

Cardiac function

no myocardial infarction in the last 6 months

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · Chapel Hill, North Carolina

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06727773 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage I or II or III is required.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify